Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

Table 3 Ongoing long-term prophylaxis medications for HAE reported in patients enrolled in IOS

All long-term prophylaxis medications reported at any time during follow-up in IOS are included in the summary; patients may be included in more than one category
HAE hereditary angioedema, IOS Icatibant Outcome Survey
^aIncludes Berinert®, Cinryze®, and unspecified C1 inhibitors

ISSN: 1710-1492